CAMPS: Case Management and Peer Support Groups for Prophylaxis Adherence in Rheumatic Heart Disease

Sponsor
Children's Hospital Medical Center, Cincinnati (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05502042
Collaborator
Uganda Heart Institute (Other)
200
2
12.6

Study Details

Study Description

Brief Summary

The objective of CAMPS is to test and evaluate scalable models of secondary antibiotic adherence support for children newly diagnosed with rheumatic heart disease.

Aim 1: Determine 1-year BPG adherence rates of children newly diagnosed with latent RHD in Uganda randomized to two support strategies: (1) Usual care (Arm 1) (2) peer group + case manager strategy (Arm 2).

Aim 2: Explore patient reported outcomes including treatment satisfaction, patient health-related quality of life, and care giver quality of life, in relation to support strategy and adherence.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Case Manager and Peer Support Group
N/A

Detailed Description

While significant strides have been made in echo screening for early detection of RHD and establishment of RHD registries, these efforts are diluted by poor adherence to secondary antibiotic prophylaxis (SAP). In a systematic review by Kevat et al which included 20 global programs, only 20% were able to maintain patients on at least 80% adherence (the minimum acceptable level). Other studies demonstrate similar findings, with adherence ranging from as low as 20% up to 75%. These studies demonstrate that non-adherence undermines most global SAP programs.

Despite low adherence to RHD secondary prophylaxis globally, studies have demonstrated that ideal RHD SAP adherence can be achieved, but within the confines of strict trial conditions (GOAL Trial). Currently, there is a dearth of research into pragmatic, scalable approaches to improve RHD SAP adherence. In their systematic review of effectiveness and integration of RHD prevention and control programs, Abrams et. al. advise that prevention and treatment programs should be integrated into general health systems and strengthen local systems. Case Managers and Peer Support Groups (CAMPS) will be a pragmatic randomized trial of two support strategies for rheumatic heart disease secondary antibiotic prophylaxis, integrated into routine care. Hence, CAMPS will address the gap that exists between ideal adherence achieved within the confines of a strict research trial and practical and scalable solutions that can be translated to real-world settings.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Case Managers and Peer Support Groups (CAMPS) will be a pragmatic randomized trial of two support strategies for rheumatic heart disease secondary antibiotic prophylaxis, integrated into routine care.Case Managers and Peer Support Groups (CAMPS) will be a pragmatic randomized trial of two support strategies for rheumatic heart disease secondary antibiotic prophylaxis, integrated into routine care.
Masking:
Single (Outcomes Assessor)
Masking Description:
Our primary outcome, adherence to SAP, will be abstracted from copies of final Uganda Ministry of Health SAP booklets by a team member blinded to treatment allocation.
Primary Purpose:
Supportive Care
Official Title:
Case Managers and Peer Support Groups (CAMPS) for Prophylaxis Adherence in Rheumatic Heart Disease
Anticipated Study Start Date :
Aug 15, 2022
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Usual Care

Referral to a health facility (HC III, IV, or district hospital) that provide secondary antibiotic prophylaxis (every-28-day intramuscular benzathine benzylpenicillin G, BPG), receipt of a Ministry of Health secondary prophylaxis adherence booklet, and education for patient and family about the importance of SAP.

Experimental: Peer Group + Case Manager

Usual care + an assigned village health team member to provide weekly short message (SMS) (weeks 1-3) and phone (week 4) support for attendance of SAP visits and a VHT (village health team member) led peer support group held at the assigned SAP clinic of participants, that includes games/peer support/education.

Behavioral: Case Manager and Peer Support Group
Assignment of a Village health team member to provide support to the family through SMS messages (weeks 1-3) and phone call (week 4), as well as home visits as needed if no contacts are reached. These contacts are intended to provide encouragement and education to participants and families to encourage SAP and peer group attendance. Peer groups will have simple play and support activities, led by the village health team member, to improve the experience of SAP for the participating children.

Outcome Measures

Primary Outcome Measures

  1. Secondary Prophylaxis Adherence [12 months]

    Continuous adherence to intramuscular Benzathine penicillin, as determined by days of coverage (each injection = 28 days of coverage)

Secondary Outcome Measures

  1. Treatment satisfaction [6 months + 12 months]

    14-item Abbreviated Treatment Satisfaction Questionnaire (v 1.4)

  2. Patient health-related quality of life [enrollment, 6-months, 12-months]

    Pediatric Quality of Life Inventory Version 4.0 Generic Core (PedsQL 4.0) questionnaire

  3. Caregiver health-related quality of life [enrollment, 6-months, 12-months]

    Parent/caregiver module of the PedsQL 4.0

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Ages 5-17

  2. New diagnosis of latent rheumatic heart disease (RHD) as determined through school screening -

Exclusion Criteria:
  1. Medical contraindication to SAP (bleeding risk, allergy)

  2. Co-morbid conditions that have already resulted in prescription of SAP (typically HIV, sickle cell disease, renal disease)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Children's Hospital Medical Center, Cincinnati
  • Uganda Heart Institute

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sarah deLoizaga Carney, Instructor, Pediatrics, Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier:
NCT05502042
Other Study ID Numbers:
  • 2021-0789
First Posted:
Aug 16, 2022
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sarah deLoizaga Carney, Instructor, Pediatrics, Children's Hospital Medical Center, Cincinnati
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022